The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia

Blood Reviews

Volumn 26, Issue 3, 2012, Pages 123-135

  Moorman, Anthony V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Acute lymphoblastic leukaemia; Chromosomal abnormalities; Cytogenetics; Genomics; Prognostication

Indexed keywords

ASPARAGINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ABL1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; BCR GENE; CDKN2A GENE; CDKN2B GENE; CHILDHOOD LEUKEMIA; CHROMOSOME 10Q; CHROMOSOME 11Q; CHROMOSOME 12P; CHROMOSOME 13Q; CHROMOSOME 15Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 19P; CHROMOSOME 1Q; CHROMOSOME 21; CHROMOSOME 21Q; CHROMOSOME 22Q; CHROMOSOME 9Q; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME G BAND; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; COMPARATIVE GENOMIC HYBRIDIZATION; CRLF2 GENE; CYTOGENETICS; DIPLOIDY; DNA INDEXING; DOWN SYNDROME; DRUG MEGADOSE; ETV6 GENE; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE FUSION; GENE REARRANGEMENT; GENETIC PROCEDURES; HAPLOIDY; HIGH HYPERDIPLOIDY; HUMAN; IKZF1 GENE; INTRACHROMOSOMAL AMPLIFICATION OF CHROMOSOME 21; KARYOTYPE; LOW HYPODIPLOIDY; MLL GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEAR HAPLOIDY; OVERALL SURVIVAL; PAX5 GENE; PBX1 GENE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; RB1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUNX1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TCF3 GENE; ZNF384 GENE;

ADULT; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CHILD; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859209595     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.01.001     Document Type: Article

References (176)

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC, Lyon.
2. Harrison C.J., Johansson B. Acute Lymphoblastic Leukaemia. Cancer Cytogenetics 2009, 233-296. Wiley-Blackwell, New Jersey. Third Edition. S. Heim, F. Mitelman (Eds.).
3. Harewood L., Robinson H., Harris R., Al Obaidi M.J., Jalali G.R., Martineau M., et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia 2003, 17:547-553.
4. Harrison C.J., Moorman A.V., Barber K.E., Broadfield Z.J., Cheung K.L., Harris R.L., et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol 2005, 129:520-530.
5. Pallisgaard N., Hokland P., Riishoj D.C., Pedersen B., Jorgensen P. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998, 92:574-588.
6. Langabeer S.E., Walker H., Gale R.E., Wheatley K., Burnett A.K., Goldstone A.H., et al. Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party. Br J Haematol 1997, 96:736-739.
7. Paulsson K., Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2009, 48:637-660.
8. Harrison C.J., Moorman A.V., Broadfield Z.J., Cheung K.L., Harris R.L., Reza J.G., et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 2004, 125:552-559.
9. Charrin C., Thomas X., Ffrench M., Le Q.H., Andrieux J., Mozziconacci M.J., et al. A report from the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL). Blood 2004, 104:2444-2451.
10. Mullighan C.G., Downing J.R. Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol 2009, 46:3-15.
11. Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E., Dalton J.D., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758-764.
12. Kawamata N., Ogawa S., Zimmermann M., Kato M., Sanada M., Hemminki K., et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2008, 111:776-784.
13. Strefford J.C., Worley H., Barber K., Wright S., Stewart A.R., Robinson H.M., et al. Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene 2007, 26:4306-4318.
14. Schwab C.J., Jones L.R., Yigittop H., Schouten J.P., Harrison C.J. Evaluation of Multiplex Ligation-dependent Probe Amplification (MLPA) as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukaemia. Genes Chromosomes Cancer 2010, 49:1104-1113.
15. Acute Lymphoblastic Leukaemia. Professional Guidelines for Clinical Cytogenetics: Association for Clinical Cytogenetics - www.cytogenetics.org.uk 2011.
16. Romana S.P., Poirel H., Leconiat M., Flexor M.A., Jonveaux M.M.P., Macintyre E.A., et al. High-frequency of t(12;21) in childhood B-lineage acute lymphoblastic-leukemia. Blood 1995, 86:4263-4269.
17. Romana S.P., Le Coniat M., Berger R. t(12;21): a new recurrent translocation in acute lymphoblastic leukemia. Genes Chromosomes Cancer 1994, 9:186-191.
18. Golub T.R., Barker G.F., Bohlander S.K., Hiebert S.W., Ward D.C., Bray-Ward P., et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1995, 92:4917-4921.
19. Shurtleff S.A., Buijs A., Behm F.G., Rubnitz J.E., Raimondi S.C., Hancock M.L., et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995, 9:1985-1989.
20. Hann I., Vora A., Harrison G., Harrison C., Martineau M., Moorman A.V., et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001, 113:103-114.
21. Harbott J., Viehmann S., Borkhardt A., Henze G., Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997, 90:4933-4937.
22. Forestier E., Heyman M., Andersen M.K., Autio K., Blennow E., Borgstrom G., et al. Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol 2008, 140:665-672.
23. Moorman A.V., Ensor H.M., Richards S.M., Chilton L., Schwab C., Kinsey S.E., et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010, 11:429-438.
24. Conter V., Bartram C.R., Valsecchi M.G., Schrauder A., Panzer-Grumayer R., Moricke A., et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115:3206-3214.
25. Pui C.H., Campana D., Pei D., Bowman W.P., Sandlund J.T., Kaste S.C., et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009, 360:2730-2741.
26. Rubnitz J.E., Wichlan D., Devidas M., Shuster J., Linda S.B., Kurtzberg J., et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2008, 26:2186-2191.
27. Ramakers-van Woerden N.L., Pieters R., Loonen A.H., Hubeek I., van Drunen E., Beverloo H.B., et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000, 96:1094-1099.
28. Loh M.L., Goldwasser M.A., Silverman L.B., Poon W.M., Vattikuti S., Cardoso A., et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006, 107:4508-4513.
29. Jabbar Al Obaidi M.S., Martineau M., Bennett C.F., Franklin I.M., Goldstone A.H., Harewood L., et al. ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia 2002, 16:669-674.
30. Litzow M.R., Buck G.A.N., Paietta E., Dewald G.W., Fielding A.K., Ketterling R.P., et al. Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia Patients on the International UKALLXII/E2993 Trial: No Difference in Results Between B Cell Immunophenotypic Subgroups. Blood 2010, 116:232.
31. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006, 6:193-203.
32. Attarbaschi A., Mann G., Konig M., Dworzak M.N., Trebo M.M., Muhlegger N., et al. Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis. Leukemia 2004, 18:1611-1616.
33. Stams W.A., Beverloo H.B., den Boer M.L., de Menezes R.X., Stigter R.L., van DE, et al. Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome. Leukemia 2006, 20:410-416.
34. Stanchescu R., Betts D.R., Rechavi G., Amariglio N., Trakhtenbrot L. Involvement of der(12)t(12;21)(p13;q22) and as well as additional rearrangements of chromosome 12 homolog in ETV6/RUNX1-positive acute lymphoblastic leukemia. Cancer Genet Cytogenet 2009, 190:26-32.
35. Moorman A.V., Konn Z.J., Barber K.E., Wright S.L., Stewart A.R.M., Parker H., et al. The spectrum and prognostic relevance of additional abnormalities, involving 12p and 21q, in children with ETV6-RUNX1 positive acute lymphoblastic leukaemia (ALL). Blood 2008, 112:164.
36. Ko D.H., Jeon Y., Kang H.J., Park K.D., Shin H.Y., Kim H.K., et al. Native ETV6 deletions accompanied by ETV6-RUNX1 rearrangements are associated with a favourable prognosis in childhood acute lymphoblastic leukaemia: a candidate for prognostic marker. Br J Haematol 2011, 155:530-533.
37. Paulsson K., Forestier E., Lilljebjorn H., Heldrup J., Behrendtz M., Young B.D., et al. Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010, 107:21719-21724.
38. Moorman A.V., Harrison C.J., Buck G.A., Richards S.M., Secker-Walker L.M., Martineau M., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood 2007, 109:3189-3197.
39. Moorman A.V., Richards S.M., Martineau M., Cheung K.L., Robinson H.M., Jalali G.R., et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood 2003, 102:2756-2762.
40. Secker-Walker L.M., Lawler S.D., Hardisty R.M. Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. Br Med J 1978, 2:1529-1530.
41. Heerema N.A., Raimondi S.C., Anderson J.R., Biegel J., Camitta B.M., Cooley L.D., et al. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer 2007, 46:684-693.
42. Sutcliffe M.J., Shuster J.J., Sather H.N., Camitta B.M., Pullen J., Schultz K.R., et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. Leukemia 2005, 19:734-740.
43. Forestier E., Johansson B., Gustafsson G., Borgstrom G., Kerndrup G., Johannsson J., et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. Br J Haematol 2000, 110:147-153.
44. Kaspers G.J.L., Smets L.A., Pieters R., van Zantwijk C.H., van Wering E.R., Veerman A.J.P. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995, 85:751-756.
45. Whitehead V.M., Vuchich M.J., Cooley L.D., Lauer S.J., Mahoney D.H., Shuster J.J., et al. Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a pediatric oncology group study. Leuk Lymphoma 1998, 31:507-519.
46. Whitehead V.M., Vuchich M.J., Lauer S.J., Mahoney D., Carroll A.J., Shuster J.J., et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 1992, 80:1316-1323.
47. Synold T.W., Relling M.V., Boyett J.M., Rivera G.K., Sandlund J.T., Mahmoud H., et al. Blast cell methotrexate-polyglutamate accumulation in-vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic-leukemia. J Clin Invest 1994, 94:1996-2001.
48. Raimondi S.C., Pui C.H., Hancock M.L., Behm F.G., Filatov L., Rivera G.K. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 1996, 10:213-224.
49. Heerema N.A., Sather H.N., Sensel M.G., Zhang T., Hutchinson R.J., Nachman J.B., et al. Prognostic impact of trisomies of chromosomes 10, 17 and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (>50 chromosomes). J Clin Oncol 2000, 18:1876-1887.
50. Hunger S.P. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996, 87:1211-1224.
51. Barber K.E., Harrison C.J., Broadfield Z.J., Stewart A.R.M., Wright S.L., Martineau M., et al. Molecular cytogenetic characterisation of TCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukaemia. Genes Chromosomes and Cancer 2007, 46:478-486.
52. Boomer T., Varella-Garcia M., McGavran L., Meltesen L., Olsen A.S., Hunger S.P. Detection of E2A translocations in leukemias via fluorescence in situ hybridization. Leukemia 2001, 15:95-102.
53. Privitera E., Kamps M.P., Hayashi Y., Inaba T., Shapiro L.H., Raimondi S.C., et al. Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia. Blood 1992, 79:1781-1788.
54. Schultz K.R., Pullen D.J., Sather H.N., Shuster J.J., Devidas M., Borowitz M.J., et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007, 109:926-935.
55. Kager L., Lion T., Attarbaschi A., Koenig M., Strehl S., Haas O.A., et al. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. Haematologica 2007, 92:1561-1564.
56. Jeha S., Pei D., Raimondi S.C., Onciu M., Campana D., Cheng C., et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009, 23:1406-1409.
57. GFCH Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia: Correlations with Hematologic Findings and Outcome. A Collaborative Study of the Groupe Francais de Cytogenetique Hematologique. Blood 1996, 87:3135-3142.
58. Mancini M., Scappaticci D., Cimino G., Nanni M., Derme V., Elia L., et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005, 105:3434-3441.
59. Secker-Walker L.M., Prentice H.G., Durrant J., Richards S., Hall E., Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 1997, 96:601-610.
60. Secker-Walker L.M., Berger R., Fenaux P., Lai J.L., Nelken B., Garson M., et al. Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia. Leukemia 1992, 6:363-369.
61. Inaba T., Roberts W.M., Shapiro L.H., Jolly K.W., Raimondi S.C., Smith S.D., et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992, 257:531-534.
62. Hunger S.P., Devaraj P.E., Foroni L., Secker-Walker L.M., Cleary M.L. Two types of genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL. Blood 1994, 83:2970-2977.
63. Harrison C.J., Martineau M., Secker-Walker L.M. The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group karyotype database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol 2001, 113:3-10.
64. Matsunaga T., Inaba T., Matsui H., Okuya M., Miyajima A., Inukai T., et al. Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein. Blood 2004, 103:3185-3191.
65. Yeung J., Kempski H., Neat M., Bailey S., Smith O., Brady H.J. Characterization of the t(17;19) translocation by gene-specific fluorescent in situ hybridization-based cytogenetics and detection of the E2A-HLF fusion transcript and protein in patients' cells. Haematologica 2006, 91:422-424.
66. Meyer C., Schneider B., Jakob S., Strehl S., Attarbaschi A., Schnittger S., et al. The MLL recombinome of acute leukemias. Leukemia 2006, 20:777-784.
67. Meyer C., Kowarz E., Hofmann J., Renneville A., Zuna J., Trka J., et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009, 23:1490-1499.
68. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 2011, 152:141-154.
69. Pieters R., Schrappe M., De L.P., Hann I., De R.G., Felice M., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007, 370:240-250.
70. Pui C.H., Gaynon P.S., Boyett J.M., Chessells J.M., Baruchel A., Kamps W., et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002, 359:1909-1915.
71. Moorman A.V., Hagemeijer A., Charrin C., Rieder H., Secker-Walker L.M. The translocations, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 patients. Leukemia 1998, 12:805-810.
72. Robinson H.M., Martineau M., Harris R.L., Barber K.E., Jalali G.R., Moorman A.V., et al. Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia. Leukemia 2005, 19:564-571.
73. Mullighan C.G., Miller C.B., Radtke I., Phillips L.A., Dalton J., Ma J., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453:110-114.
74. Moorman A.V., Chilton L., Wilkinson J., Ensor H.M., Bown N., Proctor S.J. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010, 115:206-214.
75. Burmeister T., Schwartz S., Bartram C.R., Gokbuget N., Hoelzer D., Thiel E. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood 2008, 112:918-919.
76. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
77. Schultz K.R., Bowman W.P., Aledo A., Slayton W.B., Sather H., Devidas M., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009, 27:5175-5181.
78. Rives S., Estella J., Gomez P., Lopez-Duarte M., de Miguel P.G., Verdeguer A., et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 2011, 154:600-611.
79. Ottmann O.G., Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc Hematol Educ Program 2009, 371-381.
80. Nachman J.B., Heerema N.A., Sather H., Camitta B., Forestier E., Harrison C.J., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007, 110:1112-1115.
81. Rand V., Parker H., Russell L.J., Irving J., Jones L., Masic D., et al. Intrachromosomal amplification of chromosome 21 (iAMP21) is a primary genetic event in childhood B-cell precursor acute lymphoblastic leukaemia. Blood 2011, 117:6848-6855.
82. Robinson H.M., Harrison C.J., Moorman A.V., Chudoba I., Strefford J.C. Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage-fusion-bridge cycle. Genes Chromosomes Cancer 2007, 46:318-326.
83. Strefford J.C., van Delft F.W., Robinson H.M., Worley H., Yiannikouris O., Selzer R., et al. Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci U S A 2006, 103:8167-8172.
84. Moorman A.V., Richards S.M., Robinson H.M., Strefford J.C., Gibson B.E., Kinsey S.E., et al. Prognosis of children with acute lymphoblastic leukaemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007, 109:2327-2330.
85. Attarbaschi A., Mann G., Panzer-Grumayer R., Rottgers S., Steiner M., Konig M., et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 2008, 26:3046-3050.
86. Heerema N.A., Raetz E.A., Carroll A.J., Borowitz M.J., Devidas M., Gastier-Foster J.M., et al. iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. Blood 2011, 118. 739.
87. Cooley L.D., Chenevert S., Shuster J.J., Johnston D.A., Mahoney D.H., Carroll A.J., et al. Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Cancer Genet Cytogenet 2007, 175:117-124.
88. Perez-Vera P., Montero-Ruiz O., Frias S., Rivera-Luna R., Valladares A., Arenas D., et al. Multiple copies of RUNX1: description of 14 new patients, follow-up, and a review of the literature. Cancer Genet Cytogenet 2008, 180:129-134.
89. Dyer M.J., Akasaka T., Capasso M., Dusanjh P., Lee Y.F., Karran E.L., et al. Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?. Blood 2010, 115:1490-1499.
90. Akasaka T., Balasas T., Russell L.J., Sugimoto K.J., Majid A., Walewska R., et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2007, 109:3451-3461.
91. Chapiro E., Russell L., Radford-Weiss I., Bastard C., Lessard M., Struski S., et al. Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood 2006, 108:3560-3563.
92. Chapiro E., Russell L.J., Struski S., Cave H., Radford-Weiss I., Valle V.D., et al. A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia 2010, 24:1362-1364.
93. Russell L.J., Akasaka T., Majid A., Sugimoto Kj, Loraine Karran E., Nagel I., et al. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2008, 111:387-391.
94. Russell L.J., De Castro D.G., Griffiths M., Telford N., Bernard O., Panzer-Grumayer R., et al. A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia 2009, 23:614-617.
95. Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, et al. IGH translocations, CRLF2 deregulation and micro-deletions in adolescents and adults with acute lymphoblastic leukemia. J. Clin. Oncol. in press.
96. Russell L.J., Capasso M., Vater I., Akasaka T., Bernard O.A., Calasanz M.J., et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
97. Chapiro E., Russell L., Lainey E., Kaltenbach S., Ragu C., Della-Valle V., et al. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 2010, 24:642-645.
98. Hertzberg L., Vendramini E., Ganmore I., Cazzaniga G., Schmitz M., Chalker J., et al. Down syndrome acute lymphoblastic leukemia: a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the iBFM Study Group. Blood 2010, 115:1006-1017.
99. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., Loudin M.G., Liu W., Zhang J., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
100. Yoda A., Yoda Y., Chiaretti S., Bar-Natan M., Mani K., Rodig S.J., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010, 107:252-257.
101. Ensor H.M., Schwab C., Russell L.J., Richards S.M., Morrison H., Masic D., et al. Demographic, clinical and outcome features of children with acute lymphoblastic leukaemia and a CRLF2 rearrangement: results from the MRC ALL97 clinical trial. Blood 2011, 117:2129-2136.
102. Harvey R.C., Mullighan C.G., Chen I.M., Wharton W., Mikhail F.M., Carroll A.J., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
103. Cario G., Zimmermann M., Romey R., Gesk S., Vater I., Harbott J., et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115:5393-5397.
104. Buitenkamp T., Izraeli S., Zimmermann M., Forestier E., Heerema N.A., van den Heuvel M.M., et al. Acute lymphoblastic leukemia in children with down syndrome: a report from the Ponte Di Legno study group. Blood 2011, 118:3579.
105. Harrison C.J., Hills R.K., Moorman A.V., Grimwade D.J., Hann I., Webb D.K., et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. J Clin Oncol 2010, 28:2674-2681.
106. Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood 2010, 116:354-365.
107. Pullarkat V., Slovak M.L., Kopecky K.J., Forman S.J., Appelbaum F.R. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood 2008, 111:2563-2572.
108. Granada I., Sancho J.-M., Oriol A., Morgades M., Bethencourt C., Parody R., et al. The prognostic significance of complex karyotype in Philadelphia chromosome-negative (Ph) acute lymphoblastic leukemia (ALL) in adults is related with risk group. Blood 2007, 110:3501.
109. Chessells J.M., Harrison C.J., Watson S.L., Vora A.J., Richards S.M. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol 2002, 117:306-314.
110. Soler G., Radford-Weiss I., Ben-Abdelali R., Mahlaoui N., Ponceau J.F., Macintyre E.A., et al. Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation. Leukemia 2008, 22:1278-1280.
111. Beverloo H.B., Panagopoulos I., Isaksson M., van Wering E., van Drunen E., de Klein A., et al. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). Cancer Res 2001, 61:5374-5377.
112. Tosi S., Giudici G., Mosna G., Harbott J., Specchia G., Grosveld G., et al. Identification of new partner chromosomes involved in fusions with the ETV6 (TEL) gene in hematologic malignancies. Genes Chromosomes Cancer 1998, 21:223-229.
113. Slater R.M., von Drunen E., Kroes W.G., Weghuis D.O., van den Berg E., Smit E.M., et al. t(7;12)(q36;p13) and t(7;12)(q32;p13)-translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia 2001, 15:915-920.
114. Chessells J.M., Harrison C.J., Kempski H., Webb D.K., Wheatley K., Hann I.M., et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 2002, 16:776-784.
115. La Starza R., Aventin A., Crescenzi B., Gorello P., Specchia G., Cuneo A., et al. CIZ gene rearrangements in acute leukemia: report of a diagnostic FISH assay and clinical features of nine patients. Leukemia 2005, 19:1696-1699.
116. Heerema N.A., Sather H.N., Sensel M.G., La M.K., Hutchinson R.J., Nachman J.B., et al. Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer 2002, 94:1102-1110.
117. Fielding A.K., Rowe J.M., Richards S.M., Buck G., Moorman A.V., Durrant I.J., et al. Prospective outcome data on 267 unselected patients with Philadelphia-chromosome positive adult acute lymphoblastic leukaemia confirms superiority of allogeneic transplant over chemotherapy the pre-imatinib era. Results from the international ALL trial MRC UKALLXII/ECOG2993. Blood 2009, 113:4489-4496.
118. Paulsson K., Cazier J.B., Macdougall F., Stevens J., Stasevich I., Vrcelj N., et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A 2008, 105:6708-6713.
119. Bardini M., Spinelli R., Bungaro S., Mangano E., Corral L., Cifola I., et al. DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia 2010, 24:169-176.
120. Okamoto R., Ogawa S., Nowak D., Kawamata N., Akagi T., Kato M., et al. Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia. Haematologica 2010, 95:1481-1488.
121. Sulong S., Moorman A.V., Irving J.A., Strefford J.C., Konn Z.J., Case M.C., et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukaemia reveals genomic deletion, copy number neutral loss of heterozygosity and association with specific cytogenetic subgroups. Blood 2009, 113:100-107.
122. Heerema N.A., Sather H.N., Sensel M.G., Liu-Mares W., Lange B.J., Bostrom B.C., et al. Association of chromosome Arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. Blood 1999, 94:1537-1544.
123. Nahi H., Hagglund H., Ahlgren T., Bernell P., Hardling M., Karlsson K., et al. An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. Haematologica 2008, 93:1734-1738.
124. Mirebeau D., Acquaviva C., Suciu S., Bertin R., Dastugue N., Robert A., et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 2006, 91:881-885.
125. Usvasalo A., Savola S., Räty R., Vettenranta K., Harila-Saari A., Koistinen P., et al. CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults-An array CGH study. Leuk Res 2008, 32:1228-1235.
126. An Q., Wright S.L., Konn Z.J., Matheson E., Minto L., Moorman A.V., et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci U S A 2008, 105:17050-17054.
127. An Q., Wright S.L., Moorman A.V., Parker H., Griffiths M., Ross F.M., et al. Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11-13;q11) show recurrent involvement of genes at 20q11.21. Haematologica 2009, 94:1164-1169.
128. Familiades J., Bousquet M., Lafage-Pochitaloff M., Bene M.C., Beldjord K., De Vos J., et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia 2009, 23:1989-1998.
129. Iacobucci I., Lonetti A., Paoloni F., Papayannidis C., Ferrari A., Storlazzi C.T., et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica 2010, 95:1683-1690.
130. Mullighan C.G., Su X., Zhang J., Radtke I., Phillips L.A., Miller C.B., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360:470-480.
131. Clark R., Byatt S.A., Bennett C.F., Brama M., Martineau M., Moorman A.V., et al. Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukemia. Leukemia 2000, 14:241-246.
132. Schoumans J., Johansson B., Corcoran M., Kuchinskaya E., Golovleva I., Grander D., et al. Characterisation of dic(9;20)(p11-13;q11) in childhood B-cell precursor acute lymphoblastic leukaemia by tiling resolution array-based comparative genomic hybridisation reveals clustered breakpoints at 9p13.2 and 20q11.2. Br J Haematol 2006, 135:492-499.
133. Zachariadis V., Gauffin F., Kuchinskaya E., Heyman M., Schoumans J., Blennow E., et al. The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial. Leukemia 2011, 25:622-628.
134. Forestier E., Gauffin F., Andersen M.K., Autio K., Borgstrom G., Golovleva I., et al. Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature. Genes Chromosomes Cancer 2008, 47:149-158.
135. Pichler H., Moricke A., Mann G., Teigler-Schlegel A., Niggli F., Nebral K., et al. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Munster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. Br J Haematol 2010, 149:93-100.
136. Iacobucci I., Lonetti A., Messa F., Cilloni D., Arruga F., Ottaviani E., et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2008, 112:3847-3855.
137. Iacobucci I., Storlazzi C.T., Cilloni D., Lonetti A., Ottaviani E., Soverini S., et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009, 114:2159-2167.
138. Martinelli G., Iacobucci I., Storlazzi C.T., Vignetti M., Paoloni F., Cilloni D., et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009, 27:5202-5207.
139. Harvey R.C., Mullighan C.G., Wang X., Dobbin K.K., Davidson G.S., Bedrick E.J., et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010, 116:4874-4884.
140. Waanders E., van der Velden V.H., van der Schoot C.E., van Leeuwen F.N., van Reijmersdal S.V., de Haas V., et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011, 25:254-258.
141. Kuiper R.P., Waanders E., van der Velden V.H., van Reijmersdal S.V., Venkatachalam R., Scheijen B., et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010, 24:1258-1264.
142. Palmi C., Silvestri D., Longinotti G., Vendramini E., Conter V., Basso G., et al. Poor prognosis for IKZF1 intra-gene deletions in pediatric Ph- B-cell precursor acute lymphoblastic leukemia. Blood 2011, 118:3518.
143. Asai D., Imamura T., Suenobu S., Hasegawa D., Deguchi T., Hashii Y., et al. IKZF1 deletion is strongly associated with risk of relapse in intermediate risk group in JACLS ALL02 cohort. Blood 2011, 118:1455.
144. Gómez-Seguí I., Such E., Cervera J., Fernandez P., Zamora L., Andres M., et al. Gene microdeletions in adult and pediatric acute lymphoblastic leukemia. Blood 2011, 118:3539.
145. Beldjord K., Macintyre E., Lhéritier V., Boulland M.-L., Leguay T., Thomas X., et al. Minimal residual disease at 3 months, combined to the presence of IKZF1 deletion in B-lineage or absence of NOTCH1 pathway mutation in T-lineage, recapitulates the disease risk assessment in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia - a GRAALL study. Blood 2011, 118:572.
146. Heerema N.A., Sather H.N., Sensel M.G., Lee M.K., Hutchinson R.J., Nachman J.B., et al. Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia. J Clin Oncol 2000, 18:3837-3844.
147. Marks D.I., Kurz B.W., Link M.P., Ng E., Shuster J.J., Lauer S.J., et al. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996, 87:1155-1161.
148. Hof J., Krentz S., van Schewick C., Korner G., Shalapour S., Rhein P., et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 2011, 29:3185-3193.
149. Pui C.H., Carroll W.L., Meshinchi S., Arceci R.J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011, 29:551-565.
150. Izraeli S. Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?. Br J Haematol 2010, 151:119-131.
151. Liang D.C., Shih L.Y., Yang C.P., Hung I.J., Liu H.C., Jaing T.H., et al. Frequencies of ETV6-RUNX1 fusion and hyperdiploidy in pediatric acute lymphoblastic leukemia are lower in far east than west. Pediatr Blood Cancer 2010, 55:430-433.
152. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
153. Mitelman F., Johansson B., Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007, 7:233-245.
154. Zhang J., Mullighan C.G., Harvey R.C., Wu G., Chen X., Edmonson M., et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011, 118:3080-3087.
155. Case M., Matheson E., Minto L., Hassan R., Harrison C.J., Bown N., et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res 2008, 68:6803-6809.
156. Paulsson K., Horvat A., Strombeck B., Nilsson F., Heldrup J., Behrendtz M., et al. Mutations of FLT3, NRAS, KRAS, and PTPNII are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2008, 47:26-33.
157. Bercovich D., Ganmore I., Scott L.M., Wainreb G., Birger Y., Elimelech A., et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372:1484-1492.
158. Mullighan C.G., Zhang J., Kasper L.H., Lerach S., Payne-Turner D., Phillips L.A., et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011, 471:235-239.
159. Bailey L.C., Lange B.J., Rheingold S.R., Bunin N.J. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol 2008, 9:873-883.
160. Rowe J.M. Optimal management of adults with ALL. Br J Haematol 2009, 144:468-483.
161. Parker C., Waters R., Leighton C., Hancock J., Moorman A.V., Ancliff P., et al. Mitoxantrone improves outcome of children with first relapse of acute lymphoblastic leukemia - results of the randomized ALLR3 trial. Lancet 2010, 376:2009-2017.
162. Freyer D.R., Devidas M., La M., Carroll W.L., Gaynon P.S., Hunger S.P., et al. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood 2011, 117:3010-3015.
163. Tallen G., Ratei R., Mann G., Kaspers G., Niggli F., Karachunsky A., et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010, 28:2339-2347.
164. Fielding A.K., Richards S.M., Chopra R., Lazarus H.M., Litzow M.R., Buck G.A.N., et al. Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109:944-950.
165. Vora A.J., Potter A.M., Anderson L.M., Lilleyman J.S. Frequency and importance of change in blast cell karyotype in relapsing childhood lymphoblastic leukemia. Pediatr Hematol Oncol 1994, 11:379-386.
166. Wehrli L.A., Braun J., Buetti L.N., Hagleitner N., Hengartner H., Kuhne T., et al. Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genet Cytogenet 2009, 189:29-36.
167. Reismuller B., Attarbaschi A., Peters C., Dworzak M.N., Potschger U., Urban C., et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria-a population-based report of the Austrian Berlin-Frankfurt-Munster (BFM) Study Group. Br J Haematol 2009, 144:559-570.
168. Mullighan C.G., Phillips L.A., Su X., Ma J., Miller C.B., Shurtleff S.A., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322:1377-1380.
169. Anderson K., Lutz C., Delft FWv, Bateman C.M., Guo Y., Colman S.M., et al. Genetic variegation of clonal architecture and stem cells in leukaemia. Nature 2011, 469:356-361.
170. Davidsson J., Paulsson K., Lindgren D., Lilljebjorn H., Chaplin T., Forestier E., et al. Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. Leukemia 2010, 24:924-931.
171. Yang J.J., Bhojwani D., Yang W., Cai X., Stocco G., Crews K., et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 2008, 112:4178-4183.
172. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
173. Schotte D., Chau J.C., Sylvester G., Liu G., Chen C., van der Velden V.H., et al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 2009, 23:313-322.
174. Kuang S.Q., Tong W.G., Yang H., Lin W., Lee M.K., Fang Z.H., et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 2008, 22:1529-1538.
175. Den Boer M.L., van Slegtenhorst M., De Menezes R.X., Cheok M.H., Buijs-Gladdines J.G., Peters S.T., et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009, 10:125-134.
176. Hogan L.E., Meyer J.A., Yang J., Wang J., Wong N., Yang W., et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 2011, 118:5218-5226.